Trial Profile
An Open-Label, Multi-Center Expanded Access Program of Abemaciclib for the Treatment of Hormone Receptor Positive, HER2 Negative Advanced or Metastatic Breast Cancer in Patients With Disease Progression on Prior Therapies
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Expanded access; Therapeutic Use
- Sponsors Eli Lilly and Company
- 27 Oct 2017 Status changed from recruiting to completed.
- 13 Jun 2016 New trial record